Glycosylation Analysis of Urinary Peptidome Highlights IGF2 Glycopeptides in Association with CKD

Abstract

Chronic kidney disease (CKD) is prevalent in 10% of world’s adult population. The role of protein glycosylation in causal mechanisms of CKD progression is largely unknown. The aim of this study was to identify urinary O-linked glycopeptides in association to CKD for better characterization of CKD molecular manifestations. Urine samples from eight CKD and two healthy subjects were analyzed by CE-MS/MS and glycopeptides were identified by a specific software followed by manual inspection of the spectra. Distribution of the identified glycopeptides and their correlation with Age, eGFR and Albuminuria were evaluated in 3810 existing datasets. In total, 17 O-linked glycopeptides from 7 different proteins were identified, derived primarily from Insulin-like growth factor-II (IGF2). Glycosylation occurred at the surface exposed IGF2 Threonine 96 position. Three glycopeptides (DVStPPTVLPDNFPRYPVGKF, DVStPPTVLPDNFPRYPVG and DVStPPTVLPDNFPRYP) exhibited positive correlation with Age. The IGF2 glycopeptide (tPPTVLPDNFPRYP) showed a strong negative association with eGFR. These results suggest that with aging and deteriorating kidney function, alterations in IGF2 proteoforms take place, which may reflect changes in mature IGF2 protein. Further experiments corroborated this hypothesis as IGF2 increased plasma levels were observed in CKD patients. Protease predictions, considering also available transcriptomics data, suggest activation of cathepsin S with CKD, meriting further investigation.

Identification of novel prognostic targets in acute kidney injury using bioinformatics and next generation sequencing data analysis

“…BMI1 [327], AMH (anti-Mullerian hormone) [328], E2F1 [329], PF4 [330], VASH2 [331], GRIN1 [332], CYP11B2 [333], COMP (cartilage oligomeric matrix protein) [334], DES (desmin) [335], ANGPTL3 [336], CYP3A5 [337], DPEP1 [338], LRP2 [339], AGXT2 [340], FABP1 [341], SLC22A12 [342], CUBN (cubilin) [343], MIOX (myo-inositol oxygenase) [344], ARG2 [345], KHK (ketohexokinase) [346], CYP2C8 [347], SLC2A9 [348], GC (GC vitamin D binding protein) [349], VNN1 [350], NOX4 [351], EPHX2 [352], AKR1C3 [353], NR4A3 [354], PFKFB2 [355], SLC22A6 [356], F11 [357], SLC22A2 [358], AQP2 [171], EGF (epidermal growth factor) [359], KNG1 [360], SERPINA5 [361], KL (klotho) [362], ACE2 [363], NPNT (nephronectin) [364], SLC47A1 [358], MGAM (maltase-glucoamylase) [365], AQP3 [366], AZGP1 [367], GALNT3 [368], DPP4 [369], STC1 [370], ABCB1 [371], ERRFI1 [372], TREH (trehalase) [373], MANBA (mannosidase beta) [374], ERBB4 [375], VCAM1 [376] and ALB (albumin) [377] might play an important role in the pathophysiology of AKI. BMI1 [378], IGF2 [379], PRKCB (protein kinase C beta) [380], CCL5 [381], E2F1 [382], PF4 [111], CYP11B2 [383], WNT3A [384], COMP (cartilage oligomeric matrix protein) [385], DES (desmin) [335], ANGPTL3 [386], CYP3A5 [387], LRP2 [388], PAH (phenylalanine hydroxylase) [389], HMGCS2 [390], AGXT2 [391], FABP1 [392], CUBN (cubilin) [393], DIO1 [394], MIO...…”